These results highlight the potential of NBTXR3 + PRT + αPD1 treatment in enhancing antitumor immune responses through the dual modulation of TGF-β and TNFα pathways, suggesting a promising therapeutic strategy for effective cancer treatment. This evidence concerns the gene TNF and cancer.